AstraZeneca said on Tuesday it is working with Oracle to use artificial intelligence and real-world data to find eligible patients for clinical trials and monitor safety signals. Why it matters: recruiting patients is one of the slowest, most expensive parts of developing a new medicine, and this deal puts AI directly on that bottleneck.
October 20, 2026
What happened?
AstraZeneca announced the collaboration on Tuesday, October 20. The work combines AstraZeneca’s drug development expertise with Oracle’s AI and healthcare data capabilities to support patient matching and research. No financial terms for the collaboration were disclosed in the announcement as reported.
What will the AI actually do?
The initial work will use AI and real-world data to identify patients who are eligible for clinical trials and to watch for safety signals as research proceeds. The companies say the same approach could also support earlier diagnosis of serious diseases. The first project will support hypertension research in Abu Dhabi, in partnership with UAE-based healthcare firm M42.
Which disease areas are covered?
The initial focus spans five areas: cancer, cardiovascular disease, respiratory disease, immunology and rare diseases. Those are core therapeutic areas for AstraZeneca, which is targeting more than $80 billion in annual revenue by 2030 and is looking for ways to speed up how medicines move through development.
Why it matters
Patient recruitment remains one of the biggest challenges in clinical research: delayed enrolment stretches trial timelines and pushes development costs up. AstraZeneca has felt that problem directly — Reuters notes the company has previously been hurt by trial design problems, including delays on a breast cancer drug and a failed nerve disorder treatment. This is also AstraZeneca’s second AI deal in a week, following its insitro drug-discovery collaboration announced on October 15 — but the two target different stages. Insitro’s AI hunts for new drug targets; the Oracle work starts later, when a medicine already exists and needs the right patients, fast. For readers tracking where AI earns its keep in pharma, trial operations are a less glamorous but very real test: if matching patients to studies measurably shortens trials, that is value a drugmaker can count.
Frequently asked questions
What is AstraZeneca using Oracle’s AI for?
To identify eligible patients for clinical trials using real-world data, and to monitor safety signals during research. The work may also support earlier diagnosis of serious diseases.
Where does the work start?
The first project supports hypertension research in Abu Dhabi, in partnership with UAE-based healthcare firm M42.
Which diseases does the collaboration cover?
Cancer, cardiovascular, respiratory, immunology and rare diseases.
How much is AstraZeneca paying Oracle?
No financial terms were disclosed in the announcement as reported by Reuters.
Sources: Reuters